CD274 and neoplasm: Nivolumab in combination with the ipilimumab anti-CTLA4 antibody provided a 15.6-month median survival in stage IV disease vs. 10.9 months when patients were treated with chemotherapy alone, and this benefit was independent of tumor PD-L1 expression status [14].